Free Trial
ASX:CYP

Cynata Therapeutics (CYP) Stock Price, News & Analysis

Cynata Therapeutics logo

About Cynata Therapeutics Stock (ASX:CYP)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
159,853 shs
Average Volume
N/A
Market Capitalization
A$57.60 million
P/E Ratio
N/A
Dividend Yield
13.95%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYP Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
Cynata Therapeutics Ltd (CYP) - Investing.com UK
See More Headlines

CYP Stock Analysis - Frequently Asked Questions

Cynata Therapeutics Limited (ASX:CYP) issued its earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). Cynata Therapeutics had a negative net margin of 420.82% and a negative trailing twelve-month return on equity of 100.01%.

Company Calendar

Last Earnings
2/27/2019
Today
10/16/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:CYP
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$9.74 million
Net Margins
-420.82%
Pretax Margin
N/A
Return on Equity
-100.01%
Return on Assets
-46.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.58
Quick Ratio
9.23

Sales & Book Value

Annual Sales
A$2.32 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
11.93
Book Value
A$0.04 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
180,680,000
Free Float
N/A
Market Cap
A$57.60 million
Optionable
Not Optionable
Beta
0.93
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (ASX:CYP) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners